Lupin has gained significant momentum towards development of biosimilar products with primary focus on regulated markets – Dr Cyrus Karkaria - Lupin

BSE 2296.10 NSE 2296.10

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2296.10 NSE 2296.10

Lupin has gained significant momentum towards development of biosimilar products with primary focus on regulated markets – Dr Cyrus Karkaria

December 4, 2019

-

Related Posts

January 31, 2026 Dr Cyrus Kakaria, President Biotechnology quoted in an industry story appeared in BioSpectrum India on ‘India’s Biosimilars Prowess: Transitioning to A Strategic Global Hub’
January 28, 2026 Senior General Manager and Center Head of Atharv Ability, Dr. Gaurish Kenkre’s authored article in the Health Dialogues on ‘How Daily Activities Training Restores Independence
December 23, 2025 Vinita Gupta in conversation with Business Today | Lupin doubles down on complex drugs to extend growth run

Search

Hit enter to search or ESC to close